Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD®
Open Access
- 23 June 2015
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 32 (6) , 537-547
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trialRespiratory Research, 2013
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPDNew England Journal of Medicine, 2011
- Association between lung function and exacerbation frequency in patients with COPDInternational Journal of Chronic Obstructive Pulmonary Disease, 2010
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2010
- Impact of exacerbations on COPDEuropean Respiratory Review, 2010
- Exacerbation rate, health status and mortality in COPD – a review of potential interventionsInternational Journal of Chronic Obstructive Pulmonary Disease, 2009
- A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2008
- The Impact of Severe Exacerbations on Quality of Life and the Clinical Course of Chronic Obstructive Pulmonary DiseaseThe American Journal of Medicine, 2006
- Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax, 2005